Free tool
FAERS Monitor: Norpace
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017447 or its brand name (Norpace, Disopyramide Phosphate). Reports on generic versions are filed under their own applications.
Reports
853
Serious
470
55% of reports
Hospitalization
217
Death reported
40
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective140
- off label use59
- atrial fibrillation48
- dyspnoea44
- malaise43
- fatigue42
- palpitations32
- dizziness31
- asthenia27
- feeling abnormal27
- drug interaction23
- product use issue23
- constipation22
- drug ineffective for unapproved indication22
- loss of consciousness22
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 21 |
| 2005 | 36 |
| 2006 | 13 |
| 2007 | 21 |
| 2008 | 13 |
| 2009 | 13 |
| 2010 | 42 |
| 2011 | 51 |
| 2012 | 53 |
| 2013 | 26 |
| 2014 | 71 |
| 2015 | 144 |
| 2016 | 31 |
| 2017 | 46 |
| 2018 | 18 |
| 2019 | 27 |
| 2020 | 44 |
| 2021 | 35 |
| 2022 | 49 |
| 2023 | 21 |
| 2024 | 19 |
| 2025 | 40 |
| 2026 | 19 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,306 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| atrial fibrillationSignal | 48 | 12.2 | 9.2 | 482 |
| drug ineffective for unapproved indicationSignal | 22 | 9.9 | 6.5 | 167 |
| palpitationsSignal | 32 | 6.7 | 4.8 | 152 |
| loss of consciousnessSignal | 22 | 4.2 | 2.8 | 51 |
| drug interactionSignal | 23 | 3.6 | 2.4 | 40 |
| product use issueSignal | 23 | 3.0 | 2.0 | 29 |
| feeling abnormalSignal | 27 | 2.8 | 1.9 | 29 |
| drug ineffectiveSignal | 140 | 2.6 | 2.3 | 148 |
| constipationSignal | 22 | 2.5 | 1.6 | 18 |
| malaiseSignal | 43 | 2.4 | 1.8 | 35 |
| dyspnoea | 44 | 1.9 | 1.4 | 19 |
| asthenia | 27 | 1.8 | 1.2 | 8 |
| off label use | 59 | 1.7 | 1.3 | 16 |
| dizziness | 31 | 1.5 | 1.1 | 5 |
| fatigue | 42 | 1.3 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.